

Cambridge University Press & Assessment  
978-1-108-44746-1 — The Clozapine Handbook: Stahl's Handbooks  
Jonathan M. Meyer , Stephen M. Stahl  
Frontmatter  
[More Information](#)

# The Clozapine Handbook

# The Clozapine Handbook

Stahl's Handbooks

Jonathan M. Meyer

University of California, San Diego

Stephen M. Stahl

University of California, San Diego

With illustrations by

Nancy Muntner

Neuroscience Education Institute



**CAMBRIDGE**  
UNIVERSITY PRESS

Cambridge University Press & Assessment  
978-1-108-44746-1 — The Clozapine Handbook: Stahl's Handbooks  
Jonathan M. Meyer, Stephen M. Stahl  
Frontmatter  
[More Information](#)

## CAMBRIDGE UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom  
One Liberty Plaza, 20th Floor, New York, NY 10006, USA  
477 Williamstown Road, Port Melbourne, VIC 3207, Australia  
314–321, 3rd Floor, Plot 3, Splendor Forum, Jasola District Centre, New Delhi – 110025, India  
103 Penang Road, #05–06/07, Visioncrest Commercial, Singapore 238467

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning, and research at the highest international levels of excellence.

[www.cambridge.org](http://www.cambridge.org)  
Information on this title: [www.cambridge.org/9781108447461](http://www.cambridge.org/9781108447461)  
DOI: 10.1017/9781108553575

© Jonathan M. Meyer and Stephen M. Stahl 2020

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2020  
Reprinted 2021

Printed in the United Kingdom by TJ Books Limited, Padstow Cornwall

*A catalogue record for this publication is available from the British Library.*

### *Library of Congress Cataloging-in-Publication Data*

Names: Meyer, Jonathan M., 1962– author. | Stahl, Stephen M., 1951– author. |

Title: The clozapine handbook / Jonathan M. Meyer, Stephen M. Stahl.

Other titles: Stahl's handbooks.

Description: Cambridge ; New York, NY : Cambridge University Press, 2019. | Series: Stahl's handbooks | Includes bibliographical references and index.

Identifiers: LCCN 2018054843 | ISBN 9781108447461 (paperback : alk. paper)

Subjects: | MESH: Clozapine – administration & dosage | Clozapine – therapeutic use |

Clozapine – adverse effects | Antipsychotic Agents | Schizophrenia – drug therapy

Classification: LCC RM333.5 | NLM QV 77.9 | DDC 615.7/882–dc23

LC record available at <https://lcn.loc.gov/2018054843>

ISBN 978-1-108-44746-1 Paperback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this book to provide accurate and up-to-date information that is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors, and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors, and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Cambridge University Press &amp; Assessment

978-1-108-44746-1 — The Clozapine Handbook: Stahl's Handbooks

Jonathan M. Meyer, Stephen M. Stahl

Frontmatter

[More Information](#)

Jonathan M. Meyer, M.D. is a Clinical Professor of Psychiatry at the University of California San Diego, and a Psychopharmacology Consultant to the California Department of State Hospitals. Over the past 36 months Dr. Meyer reports having served as a **consultant** to Acadia Pharmaceuticals, Alkermes, Allergan, Intra-Cellular Therapies, Merck, Neurocrine and Teva Pharmaceutical Industries; he has served on the **speakers bureaus** for Acadia Pharmaceuticals, Alkermes, Allergan, Intra-Cellular Therapies, Merck, Neurocrine, Otsuka America, Inc., Sunovion Pharmaceuticals and Teva Pharmaceutical Industries.

Stephen M. Stahl, M.D., PhD, Dsc (Hon.) is an Adjunct Professor of Psychiatry at the University of California San Diego, Honorary Visiting Senior Fellow at the University of Cambridge, UK and Director of Psychopharmacology for California Department of State Hospitals. Over the past 36 months (January 2016 – December 2018) Dr. Stahl has served as a **consultant** to Acadia, Adamas, Alkermes, Allergan, Arbor Pharmaceuticals, AstraZeneca, Avanir, Axovant, Axsome, Biogen, Biomarin, Biopharma, Celgene, Concert, ClearView, DepoMed, Dey, EnVivo, EMD Serono, Ferring, Forest, Forum, Genomind, Innovative Science Solutions, Intra-Cellular Therapies, Janssen, Jazz, Lilly, Lundbeck, Merck, Neos, Novartis, Noveida, Orexigen, Otsuka, PamLabs, Perrigo, Pfizer, Pierre Fabre, Reviva, Servier, Shire, Sprout, Sunovion, Taisho, Takeda, Taliaz, Teva, Tonix, Trius, Vanda, Vertex and Viforpharma; he has been a **board member** of RCT Logic and Genomind; he has served on **speakers bureaus** for Acadia, Astra Zeneca, Dey Pharma, EnVivo, Eli Lilly, Forum, Genentech, Janssen, Lundbeck, Merck, Otsuka, PamLabs, Pfizer Israel, Servier, Sunovion and Takeda and he has received **research and/or grant support** from Acadia, Alkermes, AssureX, Astra Zeneca, Arbor Pharmaceuticals, Avanir, Axovant, Biogen, Braeburn Pharmaceuticals, BristolMyer Squibb, Celgene, CeNeRx, Cephalon, Dey, Eli Lilly, EnVivo, Forest, Forum, GenOmind, Glaxo Smith Kline, Intra-Cellular Therapies, ISSWSH, Janssen, JayMac, Jazz, Lundbeck, Merck, Mylan, Neurocrine, Neuronetics, Novartis, Otsuka, PamLabs, Pfizer, Reviva, Roche, Sepracor, Servier, Shire, Sprout, Sunovion, TMS NeuroHealth Centers, Takeda, Teva, Tonix, Vanda, Valeant and Wyeth

**All illustrations by Nancy Muntner provided by permission of Neuroscience Education Institute.**

Contents

Foreword	ix
Introduction	1
1. The Efficacy Story: Treatment-Resistant Schizophrenia, Psychogenic Polydipsia, Treatment-Intolerant Schizophrenia, Suicidality, Violence, Mania and Parkinson’s Disease Psychosis	10
2. Addressing Clozapine Positive Symptom Nonresponse in Schizophrenia Spectrum Patients	44
3. Initiating Clozapine	60
4. Discontinuing Clozapine and Management of Cholinergic Rebound	78
5. Binding Profile, Metabolism, Kinetics, Drug Interactions and Use of Plasma Levels	90
6. Understanding Hematologic Monitoring and Benign Ethnic Neutropenia	114
7. Managing Constipation	140
8. Managing Sedation, Orthostasis and Tachycardia	158
9. Managing Sialorrhea	172
10. Managing Seizure Risk and Stuttering	190
11. Managing Metabolic Adverse Effects	204

CONTENTS

12.	Fever, Myocarditis, Interstitial Nephritis, DRESS, Serositis and Cardiomyopathy	224
13.	Managing Enuresis and Incontinence, Priapism, Venous Thromboembolism, Neuroleptic Malignant Syndrome, Tardive Dyskinesia and Obsessive Compulsive Disorder	242
14.	Eosinophilia, Leukocytosis, Thrombocytopenia, Thrombocytosis, Anemia, Hepatic Function Abnormalities	258
15.	Special Topics: Child and Adolescent Patients, Elderly Patients, Patients with Intellectual Disability, Pregnancy and Risk for Major Congenital Malformation, Lactation, Overdose, Postmortem Redistribution	276
	Index	307

## Foreword

It is 30 years since the Clozaril Collaborative Study Group published the pivotal trial results in September 1988 that established clozapine's efficacy in treatment-resistant schizophrenia, with subsequent research noting clozapine's unique benefit for suicidal and persistently aggressive schizophrenia patients [1–3]. Over the ensuing decades no other medication has proven effective for this multiplicity of uses, yet many candidate patients throughout the world are deprived of a clozapine trial. That clozapine is underutilized has been lamented in numerous publications, and remains a source of consternation for the psychiatric profession as treatment-resistant patients are repeatedly exposed to ineffective medications with little likelihood of response.

Yet, there is hope in reversing the long-standing problem of mental health clinicians refusing to prescribe a potentially effective and in some instances life-saving/life-changing medication. The past half decade has seen the rise of initiatives to increase clozapine use in certain parts of Europe and the United States, efforts that are informed by a body of literature documenting the benefits accrued to the individual, as well as to a society at large that bears the economic and social burdens of managing treatment-resistant schizophrenia. In 2015 the United States Food and Drug Administration (FDA) modernized and streamlined its clozapine prescribing guidelines, and in doing so created an evidenced-based model that can be emulated throughout the world. There have also been advances in our understanding of effective strategies to manage common adverse effects such as sialorrhea and constipation, and data-driven approaches to more vexing problems such as fever occurring during the initial 6–8 weeks of clozapine treatment.

Despite overwhelming international support in favor of increased clozapine access, one stumbling block is the need to support and nurture relevant clinicians, many of whom cite lack of education regarding clozapine's nuances as a primary reason to avoid prescribing this medication [4,5]. The present volume thus appears at an opportune time, and, in a comprehensive manner, covers the latest information and updated guidelines in a practical and easily accessible format. Nowhere is this breadth

Cambridge University Press & Assessment  
978-1-108-44746-1 — The Clozapine Handbook: Stahl's Handbooks  
Jonathan M. Meyer , Stephen M. Stahl  
Frontmatter  
[More Information](#)

---

## FOREWORD

of information and clinical insights about clozapine use provided within a single volume; moreover, of great benefit to clinicians is the manner in which Dr. Meyer and Dr. Stahl walk the reader through common issues in clozapine management and present a rationale for the next steps.

The time has come to turn the tide on the regrettable practice patterns that lead to clozapine underutilization. It is hoped that clinicians and health-care systems will take advantage of this valuable handbook to increase patient access to clozapine.

John M. Kane MD

*Professor and Chairman, Department of Psychiatry, The Donald and Barbara  
Zucker School of Medicine at Hofstra/Northwell*

*Senior Vice President, Behavioral Health Services,  
Northwell Health*



Cambridge University Press & Assessment  
978-1-108-44746-1 — The Clozapine Handbook: Stahl's Handbooks  
Jonathan M. Meyer, Stephen M. Stahl  
Frontmatter  
[More Information](#)

## FOREWORD



## References

1. Kane, J., Honigfeld, G., Singer, J., et al. (1988). Clozapine for the treatment-resistant schizophrenia. A double-blind comparison with chlorpromazine. *Archives of General Psychiatry*, 45, 789–796.
2. Meltzer, H. Y., Alphas, L., Green, A. I., et al. (2003). Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). *Archives of General Psychiatry*, 60, 82–91.
3. Krakowski, M. I., Czobor, P., Citrome, L., et al. (2006). Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. *Archives of General Psychiatry*, 63, 622–629.
4. Nielsen, J., Dahm, M., Lublin, H., et al. (2010). Psychiatrists' attitude towards and knowledge of clozapine treatment. *Journal of Psychopharmacology*, 24, 965–971.
5. Cohen, D. (2014). Prescribers fear as a major side-effect of clozapine. *Acta Psychiatrica Scandinavica*, 130, 154–155.